Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.

The design, synthesis, in vitro inhibitory potency, and pharmacokinetic (PK) profiles of Ko143 analogs are described. Compared to commonly used Ko143, the new breast cancer resistance protein (BCRP) inhibitor (compound A) showed the same potency and a significantly improved PK profile in rats (lower clearance [1.54L/h/kg] and higher bioavailability [123%]). Ko143 on the other hand suffers from poor bioavailability. Compared to Ko143, compound A would be a useful probe for delineating the role of BCRP during in vivo studies in animals.

[1]  M. Hawkins,et al.  Bryostatin-I—An Antineoplastic Treasure from the Deep? , 2002, Cancer biology & therapy.

[2]  T. Skrydstrup,et al.  Stereocontrolled synthesis of 2-substituted-1,3-azasilaheterocycles. , 2010, Organic letters.

[3]  J. Schellens,et al.  Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. , 2002, Molecular cancer therapeutics.

[4]  Yuexian Li,et al.  Synthesis of potent BCRP inhibitor-Ko143 , 2008 .

[5]  C. Xia,et al.  EXPRESSION, LOCALIZATION, AND FUNCTIONAL CHARACTERISTICS OF BREAST CANCER RESISTANCE PROTEIN IN CACO-2 CELLS , 2005, Drug Metabolism and Disposition.

[6]  Ming Zhao,et al.  Toward breast cancer resistance protein (BCRP) inhibitors: design, synthesis of a series of new simplified fumitremorgin C analogues , 2007 .

[7]  Y. Tanabe,et al.  Me2NSO2Cl and N,N-dimethylamines; a novel and efficient agent for esterification, amidation between carboxylic acids, and equimolar amounts of alcohols and amines , 2001 .

[8]  J. Reis,et al.  Accelerating lead optimization of chromone carboxamide scaffold throughout microwave-assisted organic synthesis , 2011 .

[9]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[10]  Leslie Z. Benet,et al.  Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.

[11]  R. Ford,et al.  The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone. , 2010, Structure.

[12]  P. Bailey,et al.  Use of the kinetically controlled Pictet–Spengler reaction in the asymmetric synthesis of indole alkaloids: formal syntheses of (–)-ajmaline, (–)-koumine, (–)-taberpsychine, (–)-koumidine and (–)-suavoline , 1993 .

[13]  L. Kiessling,et al.  N-acylsulfonamide linker activation by Pd-catalyzed allylation. , 2006, Organic letters.

[14]  A. Kende,et al.  Total synthesis of (+/-)-alantrypinone by hetero Diels-Alder reaction. , 2004, The Journal of organic chemistry.

[15]  M. Wiese,et al.  Novel lead for potent inhibitors of breast cancer resistance protein (BCRP). , 2010, Bioorganic & medicinal chemistry letters.